CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Renuvion APR Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05605691
NCT05605691N/ACompleted
CompareCT.gov

A Post-Market Study In Greece Of A Minimally Invasive Lower Eyelid Treatment Utilizing The Renuvion System

Apyx Medical·interventional·Posted Nov 4, 2022·Updated Mar 26, 2025

In Brief

A clinical study evaluating Renuvion APR System for Skin Laxity. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This is a prospective, multi-center, non-randomized, single-arm study of up to 15 subjects treated with the Renuvion APR System. Subjects will receive treatment with the Renuvion APR System in the lower periorbital area on both sides of the face.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Laxity
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedNov 4, 2022
Enrollment StartOct 11, 2022
Primary CompletionMar 5, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.7 years ago

Interventions

Renuvion APR Systemdevice

The Renuvion Generator (K192867) is indicated for delivery of radiofrequency energy and/or helium plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The Renuvion APR Handpiece (K191542) is intended to be used with compatible electrosurgical generators for the delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue during open surgical procedures. Together, the Renuvion Generator and Handpiece are referred to as the Renuvion APR System.